BioSpace News Archive

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced that Executive Directors of the company will present at several reputed international conferences in September, all of them to be held virtually.

The study was designed to look at the effects on bone mineral density of abaloparatide delivered via a novel transdermal device compared with the current subcutaneous formulation, marketed as TYMLOS®.

Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced pre-publication of a manuscript titled “Preclinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection.”

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, announced that Ayala management will present at two upcoming investor conferences

Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has announced positive efficacy data from a study of its induced pluripotent stem cell -derived Cymerus™ mesenchymal stem cells in a preclinical rodent model of idiopathic pulmonary fibrosis.

Agreement includes board position and exclusive negotiation period for further collaborative access to AuroLase® Therapy in other non-U.S. geographies.

Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced that it has closed on an initial $3 million in a Series B-1 financing with total approved capital of up to $6 mi

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it will provide a corporate update at the 22 nd HC Wainwright Annual Global Investment Conference. The conference will take place virtually September 14 – 16, 2020.

“Simple and Affordable Salt Spray Uses Everyday Household Ingredients to Help Protect You Against the Coronavirus” As Featured on FOX 26 Houston

Clene Nanomedicine, Inc., (“Clene”) a clinical-stage biopharmaceutical company and its Australian subsidiary, Clene Australia Pty Ltd., today announced the completion of patient enrollment in its RESCUE-ALS Phase 2 study.